![]() |
||||||
|
![]() | Fusion Gene Summary |
![]() | Fusion Gene ORF analysis |
![]() | Fusion Genomic Features |
![]() | Fusion Protein Features |
![]() | Fusion Gene Sequence |
![]() | Fusion Gene PPI analysis |
![]() | Related Drugs |
![]() | Related Diseases |
Fusion gene:CAV2-TES (FusionGDB2 ID:HG858TG26136) |
Fusion Gene Summary for CAV2-TES |
![]() |
Fusion gene information | Fusion gene name: CAV2-TES | Fusion gene ID: hg858tg26136 | Hgene | Tgene | Gene symbol | CAV2 | TES | Gene ID | 858 | 26136 |
Gene name | caveolin 2 | testin LIM domain protein | |
Synonyms | CAV | TESS|TESS-2 | |
Cytomap | ('CAV2')('TES') 7q31.2 | 7q31.2 | |
Type of gene | protein-coding | protein-coding | |
Description | caveolin-2caveolae protein, 20-kDcaveolin 2 isoform a and b | testintestis derived transcript (3 LIM domains) | |
Modification date | 20200327 | 20200313 | |
UniProtAcc | P51636 | . | |
Ensembl transtripts involved in fusion gene | ENST00000462876, ENST00000222693, ENST00000393480, ENST00000343213, | ||
Fusion gene scores | * DoF score | 3 X 3 X 2=18 | 9 X 6 X 7=378 |
# samples | 3 | 10 | |
** MAII score | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(10/378*10)=-1.91838623444635 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: CAV2 [Title/Abstract] AND TES [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | CAV2(116140501)-TES(115889074), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | CAV2-TES seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CAV2-TES seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CAV2-TES seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CAV2-TES seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CAV2-TES seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CAV2 | GO:0006906 | vesicle fusion | 12743374 |
Hgene | CAV2 | GO:0008286 | insulin receptor signaling pathway | 20455999 |
Hgene | CAV2 | GO:0016050 | vesicle organization | 12743374 |
Hgene | CAV2 | GO:0043410 | positive regulation of MAPK cascade | 20455999 |
Hgene | CAV2 | GO:0043547 | positive regulation of GTPase activity | 8552590 |
Hgene | CAV2 | GO:0048278 | vesicle docking | 12743374 |
Hgene | CAV2 | GO:0070836 | caveola assembly | 12743374 |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | HNSC | TCGA-CR-6478-01A | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
Top |
Fusion Gene ORF analysis for CAV2-TES |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-3CDS | ENST00000462876 | ENST00000358204 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
3UTR-3UTR | ENST00000462876 | ENST00000485009 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
3UTR-intron | ENST00000462876 | ENST00000393481 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
3UTR-intron | ENST00000462876 | ENST00000537767 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
5CDS-3UTR | ENST00000222693 | ENST00000485009 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
5CDS-3UTR | ENST00000393480 | ENST00000485009 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
5CDS-intron | ENST00000222693 | ENST00000393481 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
5CDS-intron | ENST00000222693 | ENST00000537767 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
5CDS-intron | ENST00000393480 | ENST00000393481 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
5CDS-intron | ENST00000393480 | ENST00000537767 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
Frame-shift | ENST00000393480 | ENST00000358204 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
In-frame | ENST00000222693 | ENST00000358204 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
intron-3CDS | ENST00000343213 | ENST00000358204 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
intron-3UTR | ENST00000343213 | ENST00000485009 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
intron-intron | ENST00000343213 | ENST00000393481 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
intron-intron | ENST00000343213 | ENST00000537767 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000222693 | CAV2 | chr7 | 116140501 | + | ENST00000358204 | TES | chr7 | 115889074 | + | 3184 | 730 | 779 | 1882 | 367 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000222693 | ENST00000358204 | CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889074 | + | 0.000695712 | 0.9993043 |
Top |
Fusion Genomic Features for CAV2-TES |
![]() |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889073 | + | 5.68E-05 | 0.99994314 |
CAV2 | chr7 | 116140501 | + | TES | chr7 | 115889073 | + | 5.68E-05 | 0.99994314 |
![]() |
![]() |
![]() |
![]() |
Top |
Fusion Protein Features for CAV2-TES |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:116140501/chr7:115889074) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
CAV2 | . |
FUNCTION: May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. Acts as an accessory protein in conjunction with CAV1 in targeting to lipid rafts and driving caveolae formation. The Ser-36 phosphorylated form has a role in modulating mitosis in endothelial cells. Positive regulator of cellular mitogenesis of the MAPK signaling pathway. Required for the insulin-stimulated nuclear translocation and activation of MAPK1 and STAT3, and the subsequent regulation of cell cycle progression (By similarity). {ECO:0000250, ECO:0000269|PubMed:15504032, ECO:0000269|PubMed:18081315}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | CAV2 | chr7:116140501 | chr7:115889074 | ENST00000222693 | + | 2 | 3 | 87_107 | 112 | 163.0 | Intramembrane | Helical |
Hgene | CAV2 | chr7:116140501 | chr7:115889074 | ENST00000222693 | + | 2 | 3 | 1_86 | 112 | 163.0 | Topological domain | Cytoplasmic |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000358204 | 1 | 7 | 234_297 | 37 | 422.0 | Domain | LIM zinc-binding 1 | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000358204 | 1 | 7 | 299_359 | 37 | 422.0 | Domain | LIM zinc-binding 2 | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000358204 | 1 | 7 | 362_421 | 37 | 422.0 | Domain | LIM zinc-binding 3 | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000358204 | 1 | 7 | 92_199 | 37 | 422.0 | Domain | PET | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000393481 | 1 | 7 | 234_297 | 28 | 413.0 | Domain | LIM zinc-binding 1 | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000393481 | 1 | 7 | 299_359 | 28 | 413.0 | Domain | LIM zinc-binding 2 | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000393481 | 1 | 7 | 362_421 | 28 | 413.0 | Domain | LIM zinc-binding 3 | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000393481 | 1 | 7 | 92_199 | 28 | 413.0 | Domain | PET |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | CAV2 | chr7:116140501 | chr7:115889074 | ENST00000343213 | + | 1 | 2 | 87_107 | 0 | 113.0 | Intramembrane | Helical |
Hgene | CAV2 | chr7:116140501 | chr7:115889074 | ENST00000222693 | + | 2 | 3 | 108_162 | 112 | 163.0 | Topological domain | Cytoplasmic |
Hgene | CAV2 | chr7:116140501 | chr7:115889074 | ENST00000343213 | + | 1 | 2 | 108_162 | 0 | 113.0 | Topological domain | Cytoplasmic |
Hgene | CAV2 | chr7:116140501 | chr7:115889074 | ENST00000343213 | + | 1 | 2 | 1_86 | 0 | 113.0 | Topological domain | Cytoplasmic |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000358204 | 1 | 7 | 22_46 | 37 | 422.0 | Compositional bias | Note=Cys-rich | |
Tgene | TES | chr7:116140501 | chr7:115889074 | ENST00000393481 | 1 | 7 | 22_46 | 28 | 413.0 | Compositional bias | Note=Cys-rich |
Top |
Fusion Gene Sequence for CAV2-TES |
![]() |
>13329_13329_1_CAV2-TES_CAV2_chr7_116140501_ENST00000222693_TES_chr7_115889074_ENST00000358204_length(transcript)=3184nt_BP=730nt CTCCCTCCAGGAAGGCCGTTGTCTTCCCTGGGACGACTTGCCAGCTCTGAGGCATGACAGTACGGGCCCCCAGAAGGGTGACCAGGAGGC CCTCCTCGTCCCAGCTGCCGGCGTCGCCGCCCACTGCAGGGCCCGGGCTGTGACTCGTGGGGACGGTTCCCTGCGCCCCGGCGGGGGAGG TGGGCGGGGAGGGGCGGCGGGGCGCCGGGGCGGGGCTCGGGACGGCCGGGCTGGGAGCTGGAGCCCACAGCGGGAAGCGGCCGCCGCCCG GGCCTCGCAGGGCTAGGCGAGGCGAGGGGGGGCGGGGCCGGGCGCTACGGGAAGGGGAGGCCGCGCGGACCGGGAGCCGCACCGCGCCAG CCGGGCTGCAGCGGCCGCGCACCAAGGCTGCGATGGGGCTGGAGACGGAGAAGGCGGACGTACAGCTCTTCATGGACGACGACTCCTACA GCCACCACAGCGGCCTCGAGTACGCCGACCCCGAGAAGTTCGCGGACTCGGACCAGGACCGGGATCCCCACCGGCTCAACTCGCATCTCA AGCTGGGCTTCGAGGATGTGATCGCAGAGCCGGTGACTACGCACTCCTTTGACAAAGTGTGGATCTGCAGCCATGCCCTCTTTGAAATCA GCAAATACGTAATGTACAAGTTCCTGACGGTGTTCCTGGCCATTCCCCTGGCCTTCATTGCGGGAATTCTCTTTGCCACCCTCAGCTGTC TGCACATCTGAAAAATATGTCGTAACTGCAAGTGTGGCCAAGAAGAGCATGATGTCCTCTTGAGCAATGAAGAGGATCGAAAAGTGGGAA AACTTTTTGAAGACACCAAGTATACCACTCTGATTGCAAAACTAAAGTCAGATGGAATTCCCATGTATAAACGCAATGTTATGATATTGA CGAATCCAGTTGCTGCCAAGAAGAATGTCTCCATCAATACAGTTACCTATGAGTGGGCTCCTCCTGTCCAGAATCAAGCATTGGCCAGGC AGTACATGCAGATGCTACCCAAGGAAAAGCAGCCAGTAGCAGGCTCAGAGGGGGCACAGTACCGGAAGAAGCAGCTGGCAAAGCAGCTCC CTGCACATGACCAGGACCCTTCAAAGTGCCATGAGTTGTCTCCCAGAGAGGTGAAGGAGATGGAGCAGTTTGTGAAGAAATATAAGAGCG AAGCTCTGGGAGTAGGAGATGTCAAACTTCCCTGTGAGATGGATGCCCAAGGCCCCAAACAAATGAACATTCCTGGAGGGGATAGAAGCA CCCCAGCAGCAGTGGGGGCCATGGAGGACAAATCTGCTGAGCACAAAAGAACTCAATATTCCTGCTATTGCTGCAAACTGAGTATGAAAG AAGGTGACCCAGCCATCTATGCCGAAAGGGCTGGCTATGATAAACTGTGGCACCCAGCTTGTTTTGTCTGCAGCACCTGCCATGAACTCC TGGTTGACATGATTTATTTTTGGAAGAATGAGAAGCTATACTGTGGCAGACATTACTGTGACAGCGAGAAACCCCGATGTGCTGGCTGTG ACGAGCTGATATTCAGCAATGAGTATACCCAGGCAGAAAACCAGAATTGGCACCTGAAACACTTCTGCTGCTTTGACTGTGATAGCATTC TAGCTGGGGAGATATACGTGATGGTCAATGACAAGCCCGTGTGCAAGCCCTGCTATGTGAAGAATCACGCTGTGGTGTGTCAAGGATGCC ACAATGCCATCGACCCAGAAGTGCAGCGGGTGACCTATAACAATTTCAGCTGGCATGCATCCACAGAGTGCTTTCTGTGCTCTTGCTGCA GCAAATGCCTCATTGGGCAGAAGTTCATGCCAGTAGAAGGGATGGTTTTCTGTTCAGTGGAATGTAAGAAGAGGATGTCTTAGGAGGAGG GCACCCAGAAGTATCGAGCCATAGCTATCCAAAGTGGTCTGCATTTCTACTGTAAAATGCAATTTGAAAAAAATAAAACGCAAAAAAAGA AACTGTAAAGGAAACCAAGAGATTTTGTTTAATTTTTTTGGCCATTTTTTCTTCATCAATTTTTTTTCGGTCTCAACTTTTAAACTTGGT TTAAGCATTTGATTTGTAAAACAGTAAATAATTGTATCTTTCCATAGCTTTTCAAATGTGAAATCATTTTTGGAAGCTTGGATCTCATTA AACTTCATGTCTCTATTCCATTTGTGCCACACACTTAAAAGTTAGTGTACTGAATGGAAAGATGAGCATTCCTAGTTCTACACTTCTTTT TTCCCCCTCATGTGTAAAATGAAAAGAAAACTAAATTTGCCCTAATACCAAGGCGCTACGTTTATTGCCTCGTCTTATTCACTGACCTTT GTAATGATACACAGTGAATTCTTTTTGACAAAGAGAAATGCAGTGTAGTATGCAGAGCTGCTGTTTTAATGCCTATGCATTTACTCTTTC CTGATTTAGGCAGAGGTGGCATTTTCTTTATTGCATTTCTCTATTTTTTTAATGTACCCTACCTTCAGTATTCTCTTTGTAAGTTGGTGA CTTGCATCTGTGGCCTTGAATATTTTATTATCACATGTGGCATAACAGTATCCACACTTTTTAGTTCTTTATTTTTTTTTTTTTATTTTG AGCAATTCTCCTGCCTCAGCCTCCCAAATAGCTGGGATTACAGGTGCATGCCACCACACCCAGCTAATTTTTGTATTTTTAGTAGAGACA GGTTTTCACCATGTTAGCCAGGCTGGTCTCAAACTCCTGACCTCAGATGATCCGCCTGCCTTGGCCTCCCAAAGTGCTGGGATTACAGGT GTGGGAGCCACCATGCCTGACCCACACACTTTTTACTTGTATAGATGATTTTTGGCTTGGACATAAAAGCCAAGCCACCCATTTGCTTTT AATCCAAAGAACATGTATAGTTTTTGTACCCAGAGACTATGATTTATATTGATTGCACTTGCCTGCCATGATTTAGATAAGATTTTTTTT GCATGGTTTTTATTCTTTCCTAATGGATCCTGTTTTATAATACTTCCAAGCCTGTCCATGGATATATCAAATGTCTTCACTTGTATATTT TCATGGCTAGGTATTTCTAATGTTTATTCTTCCCTGTGTACTTCTACACATAGCTATGCACTATGAAAATTAAATGGAATGAATGATATG TATATTACTCAAAATAAAGTTTCTTTCACTTTAA >13329_13329_1_CAV2-TES_CAV2_chr7_116140501_ENST00000222693_TES_chr7_115889074_ENST00000358204_length(amino acids)=367AA_BP= MSNEEDRKVGKLFEDTKYTTLIAKLKSDGIPMYKRNVMILTNPVAAKKNVSINTVTYEWAPPVQNQALARQYMQMLPKEKQPVAGSEGAQ YRKKQLAKQLPAHDQDPSKCHELSPREVKEMEQFVKKYKSEALGVGDVKLPCEMDAQGPKQMNIPGGDRSTPAAVGAMEDKSAEHKRTQY SCYCCKLSMKEGDPAIYAERAGYDKLWHPACFVCSTCHELLVDMIYFWKNEKLYCGRHYCDSEKPRCAGCDELIFSNEYTQAENQNWHLK HFCCFDCDSILAGEIYVMVNDKPVCKPCYVKNHAVVCQGCHNAIDPEVQRVTYNNFSWHASTECFLCSCCSKCLIGQKFMPVEGMVFCSV ECKKRMS -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CAV2-TES |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CAV2-TES |
![]() (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CAV2-TES |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | CAV2 | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
Hgene | CAV2 | C0004238 | Atrial Fibrillation | 1 | CTD_human |
Hgene | CAV2 | C0017612 | Glaucoma, Open-Angle | 1 | CTD_human |
Hgene | CAV2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | CAV2 | C0235480 | Paroxysmal atrial fibrillation | 1 | CTD_human |
Hgene | CAV2 | C0271148 | Secondary Open Angle Glaucoma | 1 | CTD_human |
Hgene | CAV2 | C0339573 | Glaucoma, Primary Open Angle | 1 | CTD_human |
Hgene | CAV2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
Hgene | CAV2 | C2585653 | Persistent atrial fibrillation | 1 | CTD_human |
Hgene | CAV2 | C3468561 | familial atrial fibrillation | 1 | CTD_human |
Tgene | C0017636 | Glioblastoma | 1 | CTD_human | |
Tgene | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human | |
Tgene | C0334588 | Giant Cell Glioblastoma | 1 | CTD_human | |
Tgene | C1621958 | Glioblastoma Multiforme | 1 | CTD_human |